Target intelligence / Profile preview

Duodenal microbiota

Molecular classification
Other
01

Overview

The duodenal microbiota refers to the complex community of microorganisms residing in the duodenum, the first section of the small intestine. Unlike the dense colonic microbiota, the duodenal environment is characterized by rapid transit, low pH, and high bile concentrations, leading to a distinct microbial profile dominated by Firmicutes and Actinobacteria (Leite et al., 2020; Kastl et al., 2020). This community plays a critical role in host health by facilitating nutrient absorption, synthesizing essential vitamins, and modulating the mucosal immune response (Kastl et al., 2020). Alterations in its composition, known as dysbiosis, are linked to various gastrointestinal and systemic conditions, including Small Intestinal Bacterial Overgrowth (SIBO), celiac disease, and metabolic disorders like Type 2 diabetes (Zhong et al., 2020; Saffouri et al., 2019). Therapeutic strategies targeting the duodenal microbiota include non-absorbable antibiotics like rifaximin, probiotics, and dietary interventions aimed at restoring homeostatic balance and improving metabolic health (Pimentel et al., 2011; Saffouri et al., 2019). Understanding the duodenal microbiota is increasingly important for developing precision medicine approaches for gastrointestinal and systemic metabolic diseases.

Other names
Duodenal microbiomeSmall intestinal microbiotaDuodenal flora
02

Mechanism of action

Modulation of microbial diversity and abundance to restore metabolic homeostasis, reduce mucosal inflammation, and regulate bile acid signaling pathways (Pimentel et al., 2011; Saffouri et al., 2019).

03

Biological functions

Nutrient metabolismImmune system modulationBile acid transformationBarrier function maintenanceVitamin synthesis
04

Disease associations

Small intestinal bacterial overgrowth (SIBO)Celiac diseaseType 2 diabetesObesityFunctional dyspepsiaNonalcoholic fatty liver disease (NAFLD)
05

Safety considerations

Risk of dysbiosisAntibiotic resistance developmentPotential for opportunistic infectionsAlteration of drug metabolism
06

Interacting drugs

Rifaximin

4 more in the full profile.

07

Biomarkers

16S rRNA sequencing profilesHydrogen/methane breath testsMicrobial diversity indicesBile acid profiles

Beyond the preview

Go deeper on Duodenal microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Duodenal microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call